503A vs 503B: the compounding difference that decides which peptides can be made at scale.

What is the difference between 503A and 503B? A 503A pharmacy compounds a drug for a named patient on a prescription and answers mainly to its state board of pharmacy. A 503B outsourcing facility can make batches without a prescription, but it must follow federal manufacturing rules and face FDA inspection. For peptides, the second door is almost shut.

Here is the argument of this piece. In a search run on 1 October 2026, most of the top results for "503A vs 503B" came from compounding pharmacies and outsourcing facilities describing their own category, and they frame the difference as two quality tiers: a smaller, state-regulated pharmacy versus a larger, FDA-inspected plant. That framing is accurate and incomplete. For anyone following the peptide debate, the difference that decides most outcomes is which raw ingredients each type of compounder may legally use. The 503B Bulks List, the federal list of ingredients outsourcing facilities may compound from, contains five substances. None is a peptide. I think that single fact explains more about where the peptide market is heading than any advisory committee vote.

Nothing below is a suggestion to use, avoid or source any compound, and nothing here is legal advice. It is a report on what the statute and the FDA say in writing, each with a date. The current legal status of each peptide, updated when it changes, is in the Ozemback peptide status tracker, and the companion piece on how the 503A Bulks List works covers the pharmacy side in more depth than this explainer does.

What is a 503A compounding pharmacy?

Section 503A of the Federal Food, Drug, and Cosmetic Act was added by the FDA Modernization Act, Public Law 105-115, signed on 21 November 1997. A 503A pharmacy or physician compounds a drug "for an identified individual patient" on a valid prescription, and in return the product is exempt from three federal requirements: FDA approval, labeling with adequate directions for use, and current good manufacturing practice (CGMP). The statute sets conditions in exchange. Bulk ingredients must meet a USP or National Formulary monograph, or be a component of an FDA-approved drug, or appear on the 503A Bulks List. A 503A pharmacy may not compound regularly or in inordinate amounts anything that is essentially a copy of a commercially available drug, and day-to-day oversight sits with state boards of pharmacy.

One condition matters more for telehealth than most readers realise. Under 21 U.S.C. 353a(b)(3)(B), a 503A compounder in a state that has not signed the FDA's standard memorandum of understanding may ship out of state no more than 5 percent of its total prescription orders. That cap is written into the statute itself. It is one reason a national telehealth brand cares which state its partner pharmacy sits in, and it is a structural limit the 503B model does not share, because outsourcing facilities are federally registered rather than tied to a single state's prescription volume.

What is a 503B outsourcing facility?

Section 503B was created by the Drug Quality and Security Act, enacted on 27 November 2013 in response to the 2012 fungal meningitis outbreak traced to contaminated injections from a Massachusetts compounder. The CDC counted 753 cases and 64 deaths across 20 states. An outsourcing facility, in the FDA's definition, is one site that compounds sterile drugs, elects to register with the FDA and complies with every condition of section 503B. It must follow CGMP, is inspected on a risk-based schedule, reports adverse events and lists everything it made each June and December. In exchange, it may ship to clinics and hospitals as office stock, without a patient-specific prescription, though it may not wholesale through a third party.

Registration also costs money every year. The FDA's notice of 30 July 2026 set fiscal year 2027 establishment fees at $22,074 for a standard outsourcing facility and $7,142 for a qualifying small business, with a reinspection fee of $21,427. The same notice estimates that 87 outsourcing facilities, including 8 small businesses, will be registered in fiscal 2027, down from 96 registrants paying fees in fiscal 2025. That is a small group of federally inspected plants, and the comparison below sets the two models side by side on the points that decide what each one can make.

Which bulk ingredients can a 503B outsourcing facility use?

The ingredient rule is where the two sections diverge most sharply. Under section 503B(a)(2), an outsourcing facility may compound from a bulk drug substance only if that substance is on the 503B Bulks List, or if the finished drug appears on the FDA drug shortage list at the time it is compounded and shipped. The ingredient must also come from an FDA-registered establishment with a valid certificate of analysis. A 503A pharmacy has a wider route: any ingredient with a USP monograph or that is a component of an approved drug qualifies, without a separate federal list. An outsourcing facility gets no such shortcut, so the 503B Bulks List does nearly all of the work for every ingredient that is not in shortage.

That list is very short. The FDA's 503B Bulks List page, with content current as of 16 May 2024, includes five substances: diphenylcyclopropenone, glycolic acid, squaric acid dibutyl ester and trichloroacetic acid, all for topical use only, and quinacrine for oral use. The same page lists 22 substances the FDA evaluated and refused, including vasopressin and nicardipine. The FDA's notice of 1 May 2026 cites nine earlier Federal Register notices on this list, from August 2018 to August 2023. It also states how the agency reads "clinical need": supply backorders do not count, convenience does not count, and the cost of a compounded drug compared with an approved one does not count.

After nine Federal Register notices since 2018, the 503B Bulks List contains five substances. None of them is a peptide.

Can a 503B outsourcing facility compound peptides?

Not from the 503B Bulks List, because no peptide is on it. What exists instead is an interim enforcement policy. Under the FDA's January 2025 guidance on 503B bulk substances, nominated ingredients were sorted into three categories, and the FDA's category document, updated 21 March 2025, is the most recent public version. Sermorelin acetate appears in 503B Category 1, which means it is under evaluation and the FDA does not intend to take action if the guidance conditions are met. That is interim non-enforcement, not a listing, and the Ozemback sermorelin file covers what it does and does not mean. Ipamorelin acetate, GHRP-2 and GHRP-6 sit in Category 2, the significant-safety-risk group, alongside the non-peptide ibutamoren.

Thymosin alpha-1 appears in Category 3, substances nominated without adequate support. BPC-157 does not appear in any of the three 503B categories in that March 2025 document, and neither does TB-500. The January 2025 guidance also ended the category system for anything nominated on or after 7 January 2025, so a peptide nominated now waits for a full clinical-need evaluation with no interim category to sit in. The practical result is plain from the documents themselves: the large, FDA-inspected compounders have almost no legal route to the peptides that dominate the current debate, and the route they do have for sermorelin is a temporary policy. The BPC-157 file sets out its own status line by line.

Does the July 2026 peptide vote change anything for 503B?

Very little, and the reason is structural. On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee voted in favour of placing BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax on the 503A Bulks List, and against emideltide; the full account of that vote is here. That vote was a recommendation. The FDA is not bound by it, formal rulemaking is still required, and as of 1 October 2026 none of those six peptides is on the 503A list. Section 503A requires the FDA to consult an advisory committee before issuing its bulks regulations. The FDA's own May 2026 notice states that section 503B does not require the agency to consult the committee before developing the 503B list.

The two lists are separate legal instruments with separate standards. If the FDA eventually finalised any of the July recommendations, that would allow a 503A pharmacy to compound the substance for a named patient on a prescription. It would not, by itself, place anything on the 503B list or let an outsourcing facility make batches for office stock. I think this is the most misread point in the coverage of the vote: even the best outcome the peptide industry is hoping for runs through the small door, one prescription at a time, and leaves the federally inspected plants where they are today.

What did the GLP-1 shortage show about the two doors?

The GLP-1 episode is the cleanest test of the shortage route. Semaglutide injection products entered the FDA shortage list in 2022, which let outsourcing facilities compound semaglutide from bulk while the shortage lasted. On 21 February 2025 the FDA issued a declaratory order that the semaglutide shortage was resolved, and gave 503A pharmacies until 22 April 2025 and 503B facilities until 22 May 2025 before enforcement resumed. The compounded GLP-1 crackdown timeline follows the business consequences. The shortage route closes the day the shortage ends, which makes it a temporary door by design.

The FDA then went after the other door. In a notice published on 1 May 2026, the agency proposed not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List, finding no demonstrated clinical need, and it extended the comment period to 30 July 2026. A search of the Federal Register on 1 October 2026 found no final determination yet. The proposal matters beyond GLP-1s because it shows how the FDA reads clinical need in practice: an approved product exists, and a lower price does not make the compounded version necessary. Any peptide nominated for the 503B list will be read against that same standard.

Isn't 503B simply the safer choice?

The strongest case for the quality-tier framing deserves a fair hearing. Outsourcing facilities follow CGMP, which means validated processes, batch release testing and documented quality systems, and they are inspected by the FDA rather than by a state board alone. Section 503B exists because a compounder without those controls shipped contaminated injections that killed 64 people. If the question is which regime imposes more manufacturing discipline, 503B wins, and the pharmacies that market their 503B registration are right to do so. Ozemback has no quarrel with that point and has made it before in its reporting on contamination in the research-peptide market.

The problem is that manufacturing discipline answers a different question from eligibility. A CGMP plant cannot legally compound an ingredient its list does not allow, and a cleaner process does not turn an unapproved substance into an approved drug. Neither 503A nor 503B products are FDA-approved, and neither section establishes that a compounded drug works. For the peptides in the news, the meaningful comparison is not "safer pharmacy versus less safe pharmacy" but "which section, if any, permits this ingredient as of today". That question has a dated answer, and on 1 October 2026 the 503B answer for BPC-157, TB-500 and the rest of the July group was no route at all.

So what is the real difference between 503A and 503B?

On paper, it is prescription versus office stock, state oversight versus FDA inspection, USP chapters versus CGMP. In practice, for peptides, it is a wide door with conditions and a narrow door that is almost closed. The 503A route accepts monograph and approved-drug ingredients and is the route the July 2026 vote addressed. The 503B route depends on a list of five topical and oral substances, a shortage list that empties when supply recovers, and an interim policy that covers sermorelin and excludes the rest. Watch the 503B list, not the advisory committee headlines, if you want to know when peptides could ever be made at industrial scale.

The letter covers each of those moves as it happens, dated and sourced, and the peptide status tracker carries the current answer for each compound in one table.

Ozemback, October 2026

Sources

1. 21 U.S.C. 353a, pharmacy compounding (FD&C Act section 503A), as added by Pub. L. 105-115, 21 November 1997. www.law.cornell.edu
2. 21 U.S.C. 353b, outsourcing facilities (FD&C Act section 503B), Drug Quality and Security Act, 27 November 2013. www.law.cornell.edu
3. FDA, Human Drug Compounding Laws, page updated 17 December 2024. www.fda.gov
4. FDA, Information for Outsourcing Facilities. www.fda.gov
5. FDA, 503B Bulk Drug Substances List, content current as of 16 May 2024. www.fda.gov
6. FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B, categories document updated 21 March 2025. www.fda.gov
7. FDA, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B, 91 FR 23431, 1 May 2026 (FR Doc. 2026-08552). www.federalregister.gov
8. FDA, extension of comment period to 30 July 2026, 26 June 2026 (FR Doc. 2026-12937). www.federalregister.gov
9. FDA, Outsourcing Facility Fee Rates for Fiscal Year 2027, 30 July 2026 (FR Doc. 2026-15342). www.federalregister.gov
10. FDA, Declaratory Order: Resolution of Shortages of Semaglutide Injection Products, 21 February 2025. www.fda.gov
11. CDC, Multistate Outbreak of Fungal Meningitis and Other Infections, 2012 (753 cases, 64 deaths, 20 states). archive.cdc.gov